<DOC>
	<DOC>NCT01594983</DOC>
	<brief_summary>This study is to determine a dose response signal for LCQ908 monotherapy and to assess the efficacy and safety of adding LCQ908 to Lovaza or fenofibrate.</brief_summary>
	<brief_title>A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Male and female subjects ages &gt;18 years of age, inclusive. History of plasma TG concentration ≥890 mg/dl (10 mmol/L) or history of lactescent plasma in the fasting state. Fasting TG ≥ 750 mg/dL (8.5 mmol/L) at day 7 or repeat of day 7 one week later for those failing to qualify initially and thought likely to qualify on repeat examination prior to randomization. Treatment with Omega3 fatty acids or niacin or fibrates within 8 weeks of screening. Patients with confirmed Familial Chylomicronemia Syndrome (FCS) with hyperlipoproteinemia (HLP) TypeI diagnosis or known to be homozygotes or compound heterozygotes for mutations in HLP Type Icausing genes (such as LPL, apoCII, CPIHBP1, or LMF1) prior to screening. Pancreatitis within 3 months prior to screening. Uncontrolled type 2 diabetes (T2DM) (as defined by an HbA1c value of ≥8.0% at screening) BMI &gt; 40 or history of bariatric surgery. Nephrotic syndrome, Type 1 diabetes, HIV, HCV or HBV positive. Estimated Glomerular Filtration Rate (eGFR) &lt; 60 ml/min/1.73m2 Other protocol defined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>hypertriglyceridemia</keyword>
	<keyword>Non familial Chylocmicronemia Syndrome (non-FCS)</keyword>
</DOC>